Is MVRBF or DGRO a better dividend investment in 2026?

MVRBF currently yields 243.90% with a 5% 5-year dividend growth rate. DGRO yields 2.13% with 9.5% growth. The better choice depends on your goal: MVRBF offers higher current income.

What is the dividend yield difference between MVRBF and DGRO?

MVRBF has a forward dividend yield of 243.90% ($2.00/share annually). DGRO yields 2.13% ($1.47/share annually). The yield gap is 241.77 percentage points.

Home › Compare › MVRBF vs DGRO

MVRBF vs DGRO: Dividend Comparison 2026

MVRBF yields 243.90% · DGRO yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MVRBF wins by $394.59M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MVRBF

● Live price

243.90%

Share price

$0.82

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$394.62M

Annual income

$218,439,906.42

Full MVRBF calculator →

DGRO

iShares Core Dividend Growth ETF

● Live price

2.13%

Share price

$68.98

Annual div

$1.47

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.6K

Annual income

$239.96

Full DGRO calculator →

Portfolio growth — MVRBF vs DGRO

📍 MVRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MVRBF	DGRO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MVRBF + DGRO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MVRBF pays

DGRO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVRBF

Annual income on $10K today (after 15% tax)

$20,731.71/yr

After 10yr DRIP, annual income (after tax)

$185,673,920.46/yr

DGRO

Annual income on $10K today (after 15% tax)

$181.24/yr

After 10yr DRIP, annual income (after tax)

$203.97/yr

At 15% tax rate, MVRBF beats the other by $185,673,716.49/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVRBF + DGRO for your $10,000?

MVRBF: 50%DGRO: 50%

100% DGRO50/50100% MVRBF

Portfolio after 10yr

$197.33M

Annual income

$109,220,073.19/yr

Blended yield

55.35%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVRBF buys

DGRO buys

No recent congressional trades found for MVRBF or DGRO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMVRBFDGRO

Forward yield	243.90% ✓	2.13%
Annual dividend / share	$2.00 ✓	$1.47
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$394.62M ✓	$31.6K
Annual income after 10y	$218,439,906.42 ✓	$239.96
Total dividends collected	$375.65M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MVRBF vs DGRO ($10,000, DRIP)

Year	MVRBF Portfolio	MVRBF Income/yr	DGRO Portfolio	DGRO Income/yr	Gap
1← crossover	$35,090	$24,390.24	$11,293	$213.22	+$23.8K → MVRBF
2	$117,533	$79,986.88	$12,730	$217.32	+$104.8K → MVRBF
3	$376,147	$250,386.00	$14,326	$221.10	+$361.8K → MVRBF
4	$1,151,374	$748,897.11	$16,098	$224.56	+$1.14M → MVRBF
5	$3,374,355	$2,142,384.97	$18,064	$227.74	+$3.36M → MVRBF
6	$9,478,533	$5,867,972.46	$20,246	$230.65	+$9.46M → MVRBF
7	$25,546,778	$15,404,747.63	$22,666	$233.30	+$25.52M → MVRBF
8	$66,138,099	$38,803,046.68	$25,349	$235.73	+$66.11M → MVRBF
9	$164,653,072	$93,885,306.32	$28,325	$237.94	+$164.62M → MVRBF
10	$394,618,693	$218,439,906.42	$31,624	$239.96	+$394.59M → MVRBF

MVRBF vs DGRO: Complete Analysis 2026

MVRBF — Stock

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Full MVRBF Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →

📬

Get this MVRBF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVRBF vs SCHD MVRBF vs JEPI MVRBF vs O MVRBF vs KO MVRBF vs MAIN MVRBF vs VIG MVRBF vs NOBL MVRBF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.